(a) Chronic kidney disease, stroke and diabetes case data may be shared with chronic kidney disease, stroke and diabetes researchers or federal chronic kidney disease, stroke and diabetes control agencies for the purposes of chronic kidney disease, stroke and diabetes prevention, control, and research upon the submittal of documentation to the Registry providing that research in chronic kidney disease, stroke and diabetes prevention or control is ongoing or approval for such research has been granted. If applicable, the Registry shall also request evidence of compliance with the requirements of 45 CFR Part 46: Protection of Human Subjects.
(b) The Registry may share statistical compilations of the chronic kidney disease, stroke and diabetes case data with state chronic kidney disease, stroke and diabetes registries and federal chronic kidney disease, stroke, and diabetes control agencies for the following reasons:(1) to perform studies on the sources and causes of chronic kidney disease, stroke and diabetes;(2) to track the changing patterns of chronic kidney disease, stroke and diabetes incidences;(3) to provide patient education and support, individualized to patients’ stage of disease and related health conditions;(4) to create a robust database of patient outcomes, perceptions, priorities, and activities that will facilitate research, clinical care, and policy decisions to improve patients’ experience and outcomes; and(5) for any other clinical, epidemiological, or other chronic kidney disease, stroke, and diabetes research.
(1) to perform studies on the sources and causes of chronic kidney disease, stroke and diabetes;
(2) to track the changing patterns of chronic kidney disease, stroke and diabetes incidences;
(3) to provide patient education and support, individualized to patients’ stage of disease and related health conditions;
(4) to create a robust database of patient outcomes, perceptions, priorities, and activities that will facilitate research, clinical care, and policy decisions to improve patients’ experience and outcomes; and
(5) for any other clinical, epidemiological, or other chronic kidney disease, stroke, and diabetes research.